uniQure: From interim to permanent
Gene therapy company uniQure NV has named Matthew Kapusta its new Chief Executive Officer. Kapusta has been interim CEO since September and also served as Chief Financial Officer for the last two years.
Before joining uniQure, Kapusta was Senior Vice President at AngioDynamics from 2011 to 2014, responsible for business development, strategic planning and national accounts.
Prior to this, he served as VP Finance for Smith & Nephew Orthopaedics. Kapusta was also Managing Director, Healthcare Investment Banking at Collins Stewart, and held various positions at Wells Fargo Securities, Robertson Stephens and PaineWebber. He holds a Master of Business Administration from New York University’s Stern School of Business, a Bachelor of Business Administration from University of Michigan’s Ross School of Business and earned his Certified Public Accountant license in 1996 while at Ernst & Young.
Adobe stock photos - https://european-biotechnology.com/latest-news/roche-moves-obesity-asset-ct-388-into-phase-iii/
X-act Cologne Clinical Research GmbH
NATO